Precision BioSciences, Inc. has announced that it will host a live webcast on March 17, 2026, at 9:00 a.m. Eastern Time, featuring key opinion leaders discussing the unmet needs and current treatment landscape for Duchenne muscular dystrophy (DMD). The event will include presentations from Dr. Aravindhan Veerapandiyan, a pediatric neurologist, and Pat Furlong, the founding president of Parent Project Muscular Dystrophy, alongside company management. The focus will be on the PBGENE-DMD program and the FUNCTION-DMD Phase 1/2 clinical trial, which aims to address the needs of approximately 60% of DMD patients. Participants can access the live webcast and presentation materials on the company's website. This event is significant as it highlights the company's commitment to advancing treatment options for DMD, a progressive neuromuscular disorder that currently lacks effective therapies. The PBGENE-DMD program is designed to provide durable functional muscle improvement and is expected to generate initial clinical data by the end of 2026. The webcast will also cover the company's operational strategies and future outlook, reinforcing its position in the biopharmaceutical industry focused on innovative gene therapies.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.